CytoSorbents Corporation (CTSO)

[pharmeng]

Thanks. At least he acknowledged they are a bit short in clinical data.

I do hope the EAP process makes them move a bit faster on sepsis. I just pray they do not go after a soft-endpoint like IL-6 reduction, but at least something like days in ICU, since that would greatly appeal to the payer side of the healthcare.

I think the fact remains that sales will not be factor for awhile, or the cardiac surgery partnership. They are just now getting to training Fresenius, so sales probably won't be until late q2 or q3. They have not started evaluations with cardiac partner, so I'm assuming it will take a few months to do that, few months to review data and come up with a potential deal.

I think only near-term catalyst is the dosing study results. My guess is it would show some positive sub-group analysis. Even though they have stated it was not supposed to show statistical significance, I am afraid of how the market will react.